Relationships between Inflammation, Adiponectin, and Oxidative Stress in Metabolic Syndrome

Shu-Ju Chen1, Chi-Hua Yen2,3,4, Yi-Chia Huang5,6, Bor-Jen Lee5,7, Simon Hsia8, Ping-Ting Lin5,6

1 Department of Health Food, Chung Chou University of Science and Technology, Changhua, Taiwan, 2 Department of Family and Community Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan, 3 School of Medicine, Chung Shan Medical University, Taichung, Taiwan, 4 Center for Education and Research on Gerontology, Chung Shan Medical University, Taichung, Taiwan, 5 School of Nutrition, Chung Shan Medical University, Taichung, Taiwan, 6 Department of Nutrition, Chung Shan Medical University Hospital, Taichung, Taiwan, 7 The Intensive Care Unit, Taichung Veterans General Hospital, Taichung, Taiwan, 8 Department of Nutrition and Institute of Biomedical Nutrition, HungKuang University, Taichung, Taiwan

Abstract

Metabolic syndrome (MS) represents a cluster of physiological and anthropometric abnormalities. The purpose of this study was to investigate the relationships between the levels of inflammation, adiponectin, and oxidative stress in subjects with MS. The inclusion criteria for MS, according to the Taiwan Bureau of Health Promotion, Department of Health, were applied to the case group (n = 72). The control group (n = 105) comprised healthy individuals with normal blood biochemical values. The levels of inflammatory markers [high sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6)], adiponectin, an oxidative stress marker (malondialdehyde), and antioxidant enzymes [catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx)] were measured. Subjects with MS had significantly higher concentrations of inflammatory markers and lower adiponectin level, and lower antioxidant enzymes activities than the control subjects. The levels of inflammatory markers and adiponectin were significantly correlated with the components of MS. The level of hs-CRP was significantly correlated with the oxidative stress marker. The IL-6 level was significantly correlated with the SOD and GPx activities, and the adiponectin level was significantly correlated with the GPx activity. A higher level of hs-CRP (≥1.00 mg/L), or IL-6 (≥1.50 pg/mL) or a lower level of adiponectin (<7.90 μg/mL) were associated with a significantly greater risk of MS. In conclusion, subjects suffering from MS may have a higher inflammation status and a higher level of oxidative stress. A higher inflammation status was significantly correlated with decreases in the levels of antioxidant enzymes and adiponectin and an increase in the risk of MS.

Introduction

Metabolic syndrome (MS) represents a clustering of physiological and anthropometric abnormalities [1] and is recognized as a significant risk factor for cardiovascular disease and type II diabetes [2]. The Third National Health and Nutrition Examination Survey (NHANES 1988–1994) reported that more than 20% of the adult population in the US suffered from MS [3,4]. A recent NHANES (2005–2006) reported that the prevalence rates of MS were 35.1% in men and 32.6% in women [5]. In Taiwan, a report from the Nutrition and Health Survey in Taiwan (NAHSIT) conducted during 1993–1996 observed that the prevalence rates of MS were 13.6% in men and 26.4% in women. A recent report from NAHSIT (2005–2008) reported that the prevalence rates of MS had increased to 25.5% in men and 31.5% in women [6]. The markers of MS, including insulin resistance, type II diabetes, hypertension, dyslipidemia, and visceral obesity, may increase oxidative stress [7–9] and reduce antioxidant defenses [10–12]. Increases in oxidative stress contribute to impaired vascular function, inflammation, thrombosis, and atherosclerosis and ultimately give rise to vascular disease [13].

The proinflammatory status may lead to the clinical and biochemical manifestations of MS [14]. In clinical studies, the levels of high sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) are commonly used as inflammatory markers that contribute the early stages of coronary artery disease [15]. hs-CRP is a product of hepatic inflammation and is under the regulation of IL-6 [16,17]; IL-6 is a messenger cytokine (pro-inflammatory cytokine) that is secreted by macrophages and smooth muscle cells in atherosclerotic lesions. Adiponectin is an anti-inflammatory marker that is potentially antiatherogenic and is secreted in abundance by adipocytes in normal subjects [14,18]. Recent clinical studies suggest that low-grade inflammation might play an important role in the pathobiology of MS [19,20]. It is worth knowing the levels of inflammatory markers and adiponectin that are associated with increased risk of MS. In addition, studies concerning the associations of the inflammation status and adiponectin with oxidative stress are limited. Therefore, the purpose of this study was to investigate the relationship between inflammatory markers (hs-CRP and IL-6), adiponectin, oxidative stress, and the components of MS. We also calculated the odds ratio of MS based on the levels of the inflammatory markers and adiponectin.
Materials and Methods

Subjects

The current study was designed as a case-control study. We expected the differences in the mean levels of hs-CRP between the case and control groups to be $1.0 \pm 1.5$ mg/L; therefore, the desired power was set at 0.8 to detect a true effect. For $\alpha = 0.05$, this power yielded a minimal sample size of 37 participants in each group. Subjects with MS (case group, n = 72) were recruited from the Department of Family and Community Medicine of Chung Shan Medical University Hospital in Taiwan. The inclusion criteria for MS in adults were based on the guidelines of the Department of Health Promotion, Department of Health, Taiwan (2007). Subjects were considered to have MS if they had three of the following five characteristics: (1) abdominal obesity (waist circumference $\geq 90$ cm in men and $\geq 80$ cm in women), (2) impaired fasting glucose ($\geq 5.6$ mmol/L), (3) hypertriglyceridemia ($\geq 1.7$ mmol/L), (4) low high-density lipoprotein cholesterol (HDL-C <1.0 mmol/L in men and <1.3 mmol/L in women), and (5) increased blood pressure (systolic blood pressure $\geq 130$ mmHg and diastolic blood pressure $\geq 85$ mmHg). Subjects using antidiabetic, antihypertensive, and lipid-lowering medications were considered to have elevated fasting blood glucose, elevated blood pressure, and dyslipidemia, respectively. Case subjects were defined as those on statin therapy were excluded. Control subjects did not have any illnesses or a history of gastrointestinal disorders, hypertension, hyperlipidemia, liver or renal disease, diabetes, or other metabolic disease. Subjects who were taking antioxidant vitamin supplements were excluded. This study was approved by the Institutional Review Board of Chung Shan Medical Hospital in Taiwan and written informed consent was obtained from each subject.

The age, blood pressures, drinking, and smoking habits of the subjects were recorded. The blood pressure was measured in each patient after resting for at least 5 min. The body weight, height, waist, and hip circumferences were measured, and the body mass index (kg/m$^2$) and the waist to hip ratio were then calculated.

Blood collection and biochemical measurement

Fasting venous blood samples (15 mL) were obtained to estimate the hematological parameters and vitamin status. Blood specimens were collected in vacutainer tubes with or without EDTA as an anticoagulant as needed. Serum and plasma were prepared and then frozen (−80°C) for storage until analysis. Blood lipid profiles [i.e., total cholesterol (TC), triacylglycerol, LDL-C, and HDL-C], and hs-CRP concentrations were measured using commercial kits (Thermo Fisher Scientific, USA).

Table 1. Characteristics of subjects.

| Characteristic                        | Case (n = 72) | Control (n = 105) | p values |
|--------------------------------------|--------------|-------------------|----------|
| Male/Female (n)                      | 43/29        | 52/53             | 0.24     |
| Age (y)                              | 53.3±11.6    | 52.0±8.1          | 0.06     |
| Systolic blood pressure (mmHg)       | 141.9±11.8   | 118.8±16.8        | <0.01    |
| Diastolic blood pressure (mmHg)      | 88.5±10.3    | 77.7±9.8          | <0.01    |
| Body mass index (kg/m$^2$)           | 29.1±5.8     | 24.4±3.5          | <0.01    |
| Waist circumference (cm)             | 96.0±12.4    | 80.6±13.6         | <0.01    |
| Waist to hip ratio                   | 0.93±0.07    | 0.85±0.11         | <0.01    |
| Fasting glucose (mmol/L)             | 7.5±2.6      | 5.2±1.1           | <0.01    |
| TC (mmol/L)                          | 4.9±1.0      | 5.1±0.9           | 0.19     |
| TG (mmol/L)                          | 1.9±0.9      | 1.3±0.6           | <0.01    |
| LDL-C (mmol/L)                       | 3.2±0.9      | 2.9±0.7           | 0.04     |
| HDL-C (mmol/L)                       | 1.2±0.3      | 1.4±0.4           | <0.01    |
| TC/HDL-C                             | 4.4±1.2      | 3.9±1.2           | <0.01    |
| Current smoker,$^2$, n (%)           | 15 (20.8%)   | 13 (12.4%)        | 0.19     |
| Drink alcohol,$^3$, n (%)            | 8 (11.1%)    | 15 (14.3%)        | 0.20     |
| Exercise,$^4$, n (%)                  | 40 (55.6%)   | 63 (60.0%)        | 0.66     |

$^1$Mean ± SD. $^2$Current smoker: individuals currently smoking one or more cigarettes per day. $^3$Drink alcohol: individuals drinking one or more drinks regularity. $^4$Exercise: individuals exercise regularly at least 3 times every week.

Control subjects did not have any illnesses or a history of gastrointestinal disorders, hypertension, hyperlipidemia, liver or renal disease, diabetes, or other metabolic disease. Subjects who were taking antioxidant vitamin supplements were excluded. This study was approved by the Institutional Review Board of Chung Shan Medical Hospital in Taiwan and written informed consent was obtained from each subject.

The age, blood pressures, drinking, and smoking habits of the subjects were recorded. The blood pressure was measured in each patient after resting for at least 5 min. The body weight, height, waist, and hip circumferences were measured, and the body mass index (kg/m$^2$) and the waist to hip ratio were then calculated.

Blood collection and biochemical measurement

Fasting venous blood samples (15 mL) were obtained to estimate the hematological parameters and vitamin status. Blood specimens were collected in vacutainer tubes with or without EDTA as an anticoagulant as needed. Serum and plasma were prepared and then frozen (−80°C) for storage until analysis. Blood lipid profiles [i.e., total cholesterol (TC), triacylglycerol, LDL-C, and HDL-C], and hs-CRP concentrations were measured using commercial kits (Thermo Fisher Scientific, USA).

| Characteristic                        | Case (n = 72) | Control (n = 105) | p values |
|--------------------------------------|--------------|-------------------|----------|
| Male/Female (n)                      | 43/29        | 52/53             | 0.24     |
| Age (y)                              | 53.3±11.6    | 52.0±8.1          | 0.06     |
| Systolic blood pressure (mmHg)       | 141.9±11.8   | 118.8±16.8        | <0.01    |
| Diastolic blood pressure (mmHg)      | 88.5±10.3    | 77.7±9.8          | <0.01    |
| Body mass index (kg/m$^2$)           | 29.1±5.8     | 24.4±3.5          | <0.01    |
| Waist circumference (cm)             | 96.0±12.4    | 80.6±13.6         | <0.01    |
| Waist to hip ratio                   | 0.93±0.07    | 0.85±0.11         | <0.01    |
| Fasting glucose (mmol/L)             | 7.5±2.6      | 5.2±1.1           | <0.01    |
| TC (mmol/L)                          | 4.9±1.0      | 5.1±0.9           | 0.19     |
| TG (mmol/L)                          | 1.9±0.9      | 1.3±0.6           | <0.01    |
| LDL-C (mmol/L)                       | 3.2±0.9      | 2.9±0.7           | 0.04     |
| HDL-C (mmol/L)                       | 1.2±0.3      | 1.4±0.4           | <0.01    |
| TC/HDL-C                             | 4.4±1.2      | 3.9±1.2           | <0.01    |
| Current smoker,$^2$, n (%)           | 15 (20.8%)   | 13 (12.4%)        | 0.19     |
| Drink alcohol,$^3$, n (%)            | 8 (11.1%)    | 15 (14.3%)        | 0.20     |
| Exercise,$^4$, n (%)                  | 40 (55.6%)   | 63 (60.0%)        | 0.66     |

$^1$Mean ± SD. $^2$Current smoker: individuals currently smoking one or more cigarettes per day. $^3$Drink alcohol: individuals drinking one or more drinks regularity. $^4$Exercise: individuals exercise regularly at least 3 times every week.

Control subjects did not have any illnesses or a history of gastrointestinal disorders, hypertension, hyperlipidemia, liver or renal disease, diabetes, or other metabolic disease. Subjects who were taking antioxidant vitamin supplements were excluded. This study was approved by the Institutional Review Board of Chung Shan Medical Hospital in Taiwan and written informed consent was obtained from each subject.

The age, blood pressures, drinking, and smoking habits of the subjects were recorded. The blood pressure was measured in each patient after resting for at least 5 min. The body weight, height, waist, and hip circumferences were measured, and the body mass index (kg/m$^2$) and the waist to hip ratio were then calculated.

Blood collection and biochemical measurement

Fasting venous blood samples (15 mL) were obtained to estimate the hematological parameters and vitamin status. Blood specimens were collected in vacutainer tubes with or without EDTA as an anticoagulant as needed. Serum and plasma were prepared and then frozen (−80°C) for storage until analysis. Blood lipid profiles [i.e., total cholesterol (TC), triacylglycerol, LDL-C, and HDL-C], and hs-CRP concentrations were measured using commercial kits (Thermo Fisher Scientific, USA).
an automated biochemical analyzer (Hitachi-7180E, Tokyo, Japan). The quantitative measurements of the serum levels of IL-6 (eBioscience, San Diego, CA, USA) and adiponectin (BioVendor, Brno, Czech Republic) were performed using commercially available enzyme-linked immunosorbent assay kits, and the absorbances were measured at 450 nm (BIO-RAD Microplate Reader Model 680, Hercules, CA, USA).

The plasma malondialdehyde (MDA) level was determined using the thiobarbituric acid reactive substances (TBARS) method [21]. Red blood cells (RBCs) were diluted with 25x sodium phosphate buffer for the SOD and GPx measurements and 250x sodium phosphate buffer for the CAT measurement. The methods for measuring the CAT, SOD and GPx activities in RBCs have previously been described [22–24]; these measurements were performed spectrophotometrically at 240 nm, 325 nm and 340 nm, respectively. The RBC protein content was determined using the BCA kit (Thermo, Rockford, IL, USA), which is based on the biuret reaction. The antioxidant enzymes activity levels were expressed as units/mg protein. All analyses were performed in duplicate and repeated measurements of the same sample varied by less than 10%. The analyses of the plasma MDA and the antioxidant enzymes activities were completed within 7 days of blood collection.

Statistical analyses

The data were analyzed using SigmaPlot software (version12.0, Systat, San Jose, CA, USA). The distribution of variables was evaluated using the Shapiro-Wilk test. The differences in the demographic and hematological characteristics between the case and control groups were analyzed using Student’s t-test or the Mann-Whitney rank sum test. For categorical response variables, differences between the two groups were assessed using the Chi-square test or Fisher’s exact test. Pearson’s correlation or Spearman rank order correlation analyses were performed to examine the correlations between the levels of inflammatory markers, adiponectin, oxidative stress, antioxidant enzymes activities, and the components of MS. Adjusted odds ratios (ORs) with 95% confidence intervals (CI) for MS were calculated from the logistic regression models based on the levels of inflammatory markers and adiponectin. The data are expressed

### Table 2. Correlations between inflammatory markers, adiponectin, and the components of metabolic syndrome.

|                         | hs-CRP (mg/L) | IL-6 (pg/mL) | Adiponectin (µg/mL) |
|-------------------------|---------------|--------------|---------------------|
| **Systolic blood pressure (mmHg)** | 0.11 (0.14)   | 0.12 (0.14)  | -0.08 (0.34)        |
| **Diastolic blood pressure (mmHg)** | 0.26 (<0.01) | 0.20 (0.01)  | -0.28 (<0.01)       |
| **Waist circumference (cm)** | 0.47 (<0.01) | 0.33 (<0.01) | -0.30 (<0.01)       |
| **Fasting glucose (mmol/L)** | 0.27 (<0.01) | 0.09 (0.26)  | -0.25 (<0.01)       |
| **TG (mmol/L)** | 0.20 (0.01)   | -0.03 (0.77) | -0.32 (<0.01)       |
| **HDL-C (mmol/L)** | -0.26 (<0.01) | -0.22 (<0.01) | 0.41 (<0.01)       |
| **hs-CRP (mg/L)** | -              | 0.46 (<0.01) | -0.24 (<0.01)       |
| **IL-6 (pg/mL)** | 0.46 (<0.01)   | -            | -0.11 (0.06)        |

1 Correlation coefficient (n = 177). HDL-C, high density lipoprotein-cholesterol; hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin-6; TG, triglyceride.

doi:10.1371/journal.pone.0045693.t002

**Table 3. Correlations between inflammatory markers, adiponectin, oxidative stress, and antioxidant enzymes activities.**

|                         | MDA (µM) | IL-6 (pg/mL) | Adiponectin (µg/mL) |
|-------------------------|----------|--------------|---------------------|
| **r^1 (p values)**     |          |              |                     |
| **MDA (µM)** | 0.13 (0.01) | 0.05 (0.56) | -0.05 (0.52)        |
| **CAT (U/mg protein)** | -0.10 (0.07) | -0.07 (0.39) | 0.04 (0.61)         |
| **SOD (U/mg protein)** | -0.16 (0.04) | -0.17 (0.04) | 0.01 (0.87)         |
| **GPx (U/mg protein)** | -0.15 (0.04) | -0.10 (0.08) | 0.12 (0.03)         |

1 Correlation coefficient (n = 177). CAT, catalase activity; GPx, glutathione peroxidase; hs-CRP, high sensitivity C-reactive protein; IL-6, interleukin-6; MDA, malondialdehyde; SOD, superoxide dismutase.

doi:10.1371/journal.pone.0045693.t003

Inflammation and Metabolic Syndrome
Table 4. The odds ratios of metabolic syndrome based on the levels of inflammatory markers and adiponectin.

|                        | Odds ratio (95% CI) | p value |
|------------------------|---------------------|---------|
| hs-CRP <1.00 mg/L      | 1.00                | -       |
| hs-CRP ≥1.00 mg/L      |                     |         |
| Model 1<sup>1</sup>    | 2.22 (1.20–4.12)    | 0.01    |
| Model 2<sup>2</sup>    | 2.42 (1.25–4.65)    | <0.01   |
| Model 3<sup>3</sup>    | 2.39 (1.16–4.94)    | 0.02    |
| IL-6 <1.50 pg/mL       | 1.00                | -       |
| IL-6 ≥1.50 pg/mL       |                     |         |
| Model 1                | 2.40 (1.13–5.11)    | <0.01   |
| Model 2                | 2.01 (1.14–3.55)    | 0.02    |
| Model 3                | 2.73 (1.08–6.94)    | 0.04    |
| Adiponectin ≥7.90 µg/mL| 1.00                | -       |
| Adiponectin <7.90 µg/mL|                     |         |
| Model 1                | 2.25 (1.02–4.96)    | 0.04    |
| Model 2                | 3.12 (1.20–8.13)    | 0.02    |
| Model 3                | 3.46 (1.20–9.99)    | 0.02    |

<sup>1</sup>None adjusted. <sup>2</sup>Adjusted for age and gender. <sup>3</sup> Adjusted for age, gender, and triglyceride.

The correlations between the levels of inflammatory markers, adiponectin, an oxidative stress, and antioxidant enzymes activities are shown in Table 3. The level of hs-CRP was significantly correlated with the level of MDA ($r = 0.13, p = 0.01$), and with the activities of CAT ($r = -0.10, p = 0.07$), SOD ($r = -0.16, p = 0.04$) and GPx ($r = -0.15, p = 0.04$). The level of IL-6 was significantly correlated with the activities of SOD ($r = -0.17, p = 0.04$) and was slightly correlated with the activities of GPx ($r = -0.10, p = 0.08$).

The correlations between the levels of inflammatory markers, adiponectin, an oxidative stress, and antioxidant enzymes activities are shown in Table 3. The level of hs-CRP was significantly correlated with the level of MDA ($r = 0.13, p = 0.01$), and with the activities of CAT ($r = -0.10, p = 0.07$), SOD ($r = -0.16, p = 0.04$) and GPx ($r = -0.15, p = 0.04$). The level of IL-6 was significantly correlated with the activities of SOD ($r = -0.17, p = 0.04$) and was slightly correlated with the activities of GPx ($r = -0.10, p = 0.08$).

The level of adiponectin was significantly correlated with the activities of GPx ($r = 0.12, p = 0.03$).

We calculated the ORs of MS based on the levels of inflammatory markers and adiponectin (Table 4). Subjects with higher levels of hs-CRP ($≥1.00$ mg/L) and IL-6 ($≥1.50$ pg/mL) or a lower level of adiponectin ($<7.90$ µg/mL) had a significantly greater risk of MS after adjusting for age, gender, and triglyceride level.

Discussion

The present study showed a statistically significant link between the levels of inflammatory markers, adiponectin, and oxidative stress in MS. Subjects with MS had higher inflammation statuses (Figure 1). A variety of features of the metabolic syndrome are associated with systemic inflammatory responses [25]. In present study, we observed that the levels of inflammatory markers (hs-CRP and IL-6) were significantly positively correlated with the components of MS; in contrast, the level of adiponectin was inversely correlated with the components of MS (Table 2). We calculated the ORs of MS according to the levels of inflammatory markers and adiponectin (Table 4). The level of hs-CRP ($1.0$ mg/L) or IL-6 ($≥1.5$ pg/mL) was used as a cut-off point to define higher inflammation status, which is an average risk factor for coronary artery disease [25,26]. Plasma level of adiponectin in human is substantially high, up to 10 to 15 µg/mL on average [18].

In the present study, we have tried to calculate the ORs of MS according to the 50<sup>th</sup> percentile of adiponectin level (5.80 µg/mL), there was no significant correlation between this level of adiponectin and the risk of MS. As a result, the 75<sup>th</sup> percentile of adiponectin level (7.90 µg/mL) was used as a cut-off point in present study. Subjects with a higher inflammation status (hs-CRP $≥1.0$ mg/L, IL-6 $≥1.50$ pg/mL or adiponectin $<7.90$ µg/mL) had a significantly increased risk of MS. It seems that chronic inflammation is part of MS [27,28] and that inflammatory markers (hs-CRP and IL-6) and adiponectin are significant risk factors for MS. We suggested the levels of inflammatory markers (hs-CRP and IL-6) and adiponectin could be incorporated in the diagnostic biomarkers for MS.

Oxidative stress is thought to play an important role in the development of MS [9]. Although the level of MDA was not significantly different between the case and control groups, the activities of CAT, SOD, and GPx were significantly lower in the case group (Figure 2). In the present study, we also assessed the correlations between inflammatory markers and oxidative stress markers. We observed that the inflammatory markers were significantly correlated with increased oxidative stress (Table 3).

In particular, subjects with higher inflammation status (hs-CRP $≥3.0$ mg/L) had significantly higher MDA level and lower antioxidant enzymes activities (data not shown). There was a significant positive correlation between inflammation status and oxidative stress, and we presume that subjects with MS may have a higher inflammation status and a higher level of oxidative stress. Antioxidant enzymes are the first line of defense against ROS and lead to a decrease in their activities [12]. In addition, MS subjects in general were typically abdominally obese. In the present study,
we observed that the value of waist circumference was significant correlated with the level of MDA in the stress such as urinary 8-epi-prostaglandin F2α, respectively. The ratio of waist to hip was significantly negative correlated with SOD \((r = -0.25, p<0.01)\) and GPx activities \((r = -0.41, p<0.01)\), respectively. The values of obesity index were significantly negative correlated with GPx activities \((r = -0.34, p<0.01)\). The values of waist circumferences were significantly positive correlated with the level of MDA in the case group \((r = 0.24, p = 0.047)\). Obesity is an oxidative burden that may lead to the reduction of antioxidant enzymes activities \[29\], and induced inflammation plays a pathogenic role in the development and progression of MS \[30\].

Our study has some limitations. First, the number of participants was small, although we did recruit more subjects than we expected to recruit. Second, this study was a cross-sectional study, and therefore, no causal relationship could be defined. Larger, prospective studies are needed to establish the relationship between inflammation and oxidative stress in MS patients. Third, we selected MDA as a oxidative stress marker and hs-CRP and IL-6 as inflammatory markers in the present study; further studies could select more sensitive markers of oxidative stress such as urinary 8-epi-prostaglandin F2α, plasma oxidized LDL or the ratio of reduced glutathione to oxidized glutathione and other important adipokines (such as tumor necrosis factor α, IL-1β, leptin, monocyte chemoattractant protein-1 or proteins of the renin angiotensin system) in subjects with MS.

In conclusion, subjects suffering from MS may have a higher inflammation status and a higher level of oxidative stress. A higher inflammation status was significantly correlated with lower the levels of antioxidant enzymes and adiponectin, and greater risk of MS.

Acknowledgments

The authors would like to express their sincere appreciation to the subjects for their participation. We thank the nurses at Chung Shan Medical University Hospital for providing expert assistance in blood sample collection and data analysis.

Author Contributions

Conceived and designed the experiments: SJC PTL. Performed the experiments: CHY SH. Analyzed the data: YCH PTL. Contributed reagents/materials/analysis tools: SJC YCH PTL. Wrote the paper: SJC PTL. Provide patients and controls: CHY BJL.

References

1. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285: 2486–2497.
2. Ferrannini E, Haffner SM, Mitchell BD, Stern MP (1991) Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 34: 416–422.
3. Ford ES, Giles WH (2003) A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 26: 575–581.
4. Park YW, Zhu S, Palaniappan L, Heshka S, Carretoni MR, et al. (2003) The metabolic syndrome: prevalence and associated risk factor findings in the U.S. population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163: 427–436.
5. Kolovou GD, Anagnostopoulou KK, Sálpá KD, Mháháilidí P (2007) The prevalence of metabolic syndrome in various populations. Am J Med Sci 333: 362–371.
6. Yeh CJ, Chang HY, Pan WH (2011) Time trend of obesity, the metabolic syndrome and related dietary pattern in Taiwan: from NANSHA 1993–1996 to NAHSIT 2005–2006. Asia Pac J Clin Nutr 20: 292–300.
7. Ceriello A, Quatraro A, Giugliano D (1993) Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress? Metabolism 42: 363–368.
8. West IC (2000) Radicals and oxidative stress in diabetes. Diabetic Med 17: 180.
9. Antoniades C, Toutouzas P, Stefanadis C (2003) Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz 26: 628–638.
10. Stocker R, Keaney JF (2004) Role of oxidative modification in atherosclerosis. Physiol Rev 84: 1381–1478.
11. Penckofer S, Scherzer D, Horozak K (2002) Oxidative stress cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. J Cardiovasc Nurs 16: 68–85.
12. Giugliano D (2000). Dietary antioxidants for cardiovascular disease prevention. Nutr Metab Cardiovasc Dis 10: 38–44.
13. Dandona P, Alijada A, Chaudhuri A, Mohanty P, Garg R (2005) Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 111: 1448–1454.
14. Luc G, Bard JM, Jahan-Vaque F, Ferrieres J, Evans A, et al. (2005) C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 23: 1253–1261.
15. Heinrich PC, Castell JV, Andus T (1999) Interleukin-6 and the acute phase response. Biochem J 345: 621–636.
16. Bataille R, Klein B (1992) C-reactive protein levels as a direct indicator of interleukin-6 levels in humans in vivo. Arthritis Rheum 35: 982–984.
17. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I (2004) Adiponectin and Metabolic Syndrome. Arterioscler Thromb Vasc Biol 24: 29–33.
18. Das UN (2004) Metabolic syndrome X: an inflammatory condition? Curr Hypertens Rep 6: 66–73.
19. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, et al. (2007) Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract 75: 235–240.
20. Lapenna D, Ciocafi G, Pierdomenico SD, Giamberrardo MA, Cucurullo F (2001) Reaction conditions affecting the relationship between thiobarbituric acid reactivity and lipid peroxides in human plasma. Free Radic Biol Med 31: 331–335.
21. Paglia D, Valentine W (1967) Studies on the qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70: 159–169.
22. Marklund S, Marklund G (1974) Involvement of superoxide anion radical in autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47: 469–474.
23. Aihara H (1984) Catalase in vitro. Methods Enzymol 105: 121–126.
24. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, et al. (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107: 499–511.
25. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH (2000) Plasma concentration of interleukin-6 and the risk future myocardial infarction among apparently healthy men. Circulation 101: 1767–72.
26. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, et al. (2004) Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23: 1833–1839.
27. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, et al. (2004) Adiponectin as a biomarker of the metabolic syndrome. J Lab Clin Med 21: 975–981.
28. Karasuyama N, Merzouk H, Arihi M, Merzouk SA, Berrouiguet AY, et al. (2011) Effects of the association of aging and obesity on lipids, lipoproteins and oxidative stress biomarkers: a comparison of older with young men. Nutr Metab Cardiovasc Dis 21: 792–799.
29. Shoelson SE, Herzog L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169–2180.